Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.

European journal of nuclear medicine and molecular imaging·2026
Same author

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease.

Brain communications·2026
Same author

Minimal clinically important difference for cognitive scales in people with Parkinson's disease with cognitive impairment.

Scientific reports·2026
Same author

Parkinson's disease-subjective cognitive decline and health-related quality of life.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Unraveling the genetic architecture of non-Huntington chorea: a biobank-scale study of rare variants and repeat expansions.

NPJ genomic medicine·2026
Same author

Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same journal

Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders).

Recent patents on CNS drug discovery·2016
Same journal

Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.

Recent patents on CNS drug discovery·2016
Same journal

Endocannabinoid System in Neurological Disorders.

Recent patents on CNS drug discovery·2016
Same journal

Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.

Recent patents on CNS drug discovery·2016
Same journal

Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.

Recent patents on CNS drug discovery·2016
Same journal

Neuropharmacological Properties of Withania somnifera - Indian Ginseng: An Overview on Experimental Evidence with Emphasis on Clinical Trials and Patents.

Recent patents on CNS drug discovery·2016
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Individual triptan selection in migraine attack therapy.

Robert Belvís1, Javier Pagonabarraga, Jaime Kulisevsky

  • 1Headache Unit, Department of Neurology, USP Dexeus University Institute, Barcelona, Spain. 32353rbn@comb.es

Recent Patents on CNS Drug Discovery
|January 20, 2009
PubMed
Summary
This summary is machine-generated.

Triptans are the first-line acute treatment for moderate-severe migraine attacks. Selecting the optimal triptan involves considering individual patient needs and drug-specific profiles for effective migraine management.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine affects 6% of men and 18% of women, significantly impacting quality of life and incurring high healthcare costs.
  • Acute treatment of moderate-to-severe migraine attacks relies on selective serotonin [5-HT1B/1T] receptor agonists, known as triptans.

Purpose of the Study:

  • To provide a state-of-the-art overview of triptan selection for moderate-to-severe migraine attacks.
  • To guide clinicians in choosing the most appropriate triptan based on drug and patient characteristics.

Main Methods:

  • Review of existing literature on seven marketed triptan molecules.
  • Analysis of pharmacokinetic and pharmacodynamic properties of different triptans and formulations.
  • Consideration of clinical migraine attack characteristics and patient-specific factors (lifestyle, medical history).

Main Results:

  • Seven triptan molecules are currently available, each with distinct properties and formulations (tablets, dissolvable, nasal, injections).
  • Triptan selection is based on efficacy, safety, pharmacokinetics, and pharmacodynamics.
  • No single clinical trial has simultaneously compared all available triptan molecules.

Conclusions:

  • The choice of triptan requires a personalized approach, integrating drug profiles with individual patient and migraine characteristics.
  • Optimizing triptan therapy can improve patient outcomes and reduce the burden of migraine.